REPLEK PHARM IN ACCORDANCE WITH THE NEW FINDINGS IN SUPPORT TO PARENTS AND CHILDREN WITH EPILEPTIC SYNDROME
US Food and Drug Agency (FDA) recently approved the use of Cannabidiol (CBD), 100mg / 10ml, 100ml oral solution for the treatment of epileptic seizures in specific forms of epilepsy (Lennox-Gastaut and Dravet syndrome) in patients older than two years (children and adults)
With this, for the first time in the United States, cannabis-containing pharmaceutical product has been approved for use in the United States, verifying World Health Organization (CBD) data on the therapeutic efficacy of CBD in epilepsy.
REPLEK PHARM to meet the needs of parents of the most vulnerable category of patients – children with severe forms of epilepsy, who may use CBD (CANOBIL® EPI 120 ml) as an additional therapy, enabled this product to be available in pharmacies at a single retail price of 4095 mkd, which was previously available at a price of 7686 mkd.
REPLEK PHARM as a Pharmaceutical Company remains committed to providing quality, efficient and safe medicines to improve our citizen’s health, especially children’s health, as most valuable and driving force for the future of our country.